Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.
“During the first quarter of 2022, we made strong progress advancing our pipeline of clinical, research and discovery programs for rare, severe chronic kidney diseases. We continue to enroll patients in the phase 3 ALIGN and phase 2 AFFINITY trials for atrasentan as well as the phase 1/2 trial of BION-1301, and we are pleased to have recently initiated the phase 1 healthy volunteer trial of CHK-336, our first internally-discovered program for the treatment of primary and idiopathic hyperoxaluria,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. “We look forward to the upcoming 59th ERA Congress being held May 19th – 22nd, where we will present clinical data from both our lead programs, atrasentan and BION-1301, in patients with IgA nephropathy (IgAN).”
Recent Accomplishments and Updates
Precision Medicine Research & Discovery
First Quarter 2022 Financial Results
About Chinook Therapeutics, Inc.
Cautionary Note on Forward-Looking Statements
Contact: Noopur Liffick Vice President, Investor Relations & Corporate Communications [email protected] [email protected]
IDEA SHOWCASE Keynote/Welcome Address - Open to all Badge Holders
Session Details TBA
IDEA SHOWCASE RECEPTION AND PITCH EVENT - Open to all Badge Holders - Sponsored by IKIN